Search results
Showing 61 to 75 of 2128 results for technology appraisal
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.
In development Reference number: GID-TA11545 Expected publication date: 11 February 2026
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.
Show all sections
Sections for TA1029
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years.
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.